I was privileged to attend the 12th Invest in ME Research International conference on 2nd June in Westminster, London. This followed a 2 day colloquium where many of the top International ME/CFS researchers had gathered to discuss their work. At the conference there was a full day of presentations by a wide range of International speakers on a variety of associated topics.

The conference was opened by Dr Ian Gibson.

The first presentation was by Dr Ian Charles (leader of the Quadram Institute, Norwich, UK), who outlined the development of the UK Centre of Excellence for ME/CFS. He told us there are likely to be approximately 250,000 with ME/CFS in the UK, of which 25,000 are children and young people. Up to 84% may not yet be diagnosed. Possible causes were outlined, which included dysbiosis of the microbiota and possible auto-reactivity to commensal microbes.

Norwich Research Park, with the interdisciplinary Quadram Institute of Food Health is Europe’s largest single-site concentration of research, and includes 3000 scientists and 14,000 students. There is a hospital on site. Research includes food science and also how the microbiome relates to the immune system and health. The study of genomics is increasingly important. Microbiome research is being addressed in many diseases.

The Quadram Institute has a long term commitment and will be the UK/Europe hub for biomedical research into ME/CFS.

A video was then shown of the enormous campus and how it will be developed to accommodate the associated research into ME/CFS. It will also include medical facilities. Dr Vicki Whittemore (NIH, USA) is programme director of the National Institute of Neurological Disorders and Stroke (NINDS). The NIH (made up of 27 institutes and centres) seeks knowledge about the nature and behaviour of living systems. The NIH is committed to ME/CFS research, both intramurally and extramurally.

A current study is looking at 40 patients, 20 controls and 20 recovered Lyme disease patients. An extensive analysis and bio-specimen collection is being undertaken. The NIH is also organising seminars for building education, clinical and research issues. There is also revitalisation of the trans-NIH ME/CFS working group. This will stimulate research to include: identification of research priorities, a common data-elements project with the CDC and
fostering of international research and collaboration. Canada is already collaborating. Funding has been significantly increased to $8 million.

Common data elements: there is need to standardise and harmonise, with development of a common language. Many working groups will be involved. Funding opportunity announcements include: Determining the aetiology and pathology of ME/CFS, identification of subtypes, long-term studies and outcome measures and potential treatment targets. A timeline for setting these up is within the next 3-6 months.

Long-term goals were discussed including support of treatment trials and improvement in quality of life.

**Professor Donald Staines** (Griffith University, Qld, Australia) discussed their paper “Impaired calcium mobilization and dysregulation of transient receptor potential melastatin 3 (TRPM3) ion channels in Natural Killer (NK) cells from CFS/ME”.

Their group were the first to identify TRPM3 on NK cells. There is impaired calcium mobilization. They also have studied NK cells, and find function and expression significantly reduced. Calcium is an important intracellular cell-signalling messenger. Biochemistry and genetics are involved. Immunological research shows a significant reduction in NK cell lysis, characterised by immune dysfunction. Because of their decreased function in ME/CFS, NK cells are a useful model to study.

Significant changes are also evident in the genetics of NK cells. SNPs may change the function. TRPM3 stood out as abnormal. Its actual role in intracellular calcium mobilization has yet to be determined. TRPM3 converts “threat” signals, and threats are managed by these channels. Calcium is the 2nd messenger in every system. Calcium is up to 1000 times higher outside the cell than inside. Receptors open pathways to do the work in the cell. TRPM3 is the predominant ion channel and its expression is down in ME/CFS. This is very important in glial cells in the brain. The calcium signals can be measured.

Unstimulated CD56 bright CD16 dim/− NK cells showed significantly reduced TRPM3 receptors in ME/CFS compared to healthy controls. Pregnenolone Sulphate (preg-S) stimulated CD56 bright CD16 dim/− NK cells increased TRPM3 expression significantly in ME/CFS, but this was not associated with a significant increase in Ca2+ flux and NK cell lysis. Thapsigargin (TG) stimulated CD56 bright CD16 dim/− NK cells significantly increased NK cell lysis prior to preg-S stimulation in patients compared to controls. This may all provide evidence for their role in the pathomechanisms involving NK cell cytotoxicity in ME/CFS.

There are significant effects in this system. Manipulation of TRPM3 function may lead to therapeutic interventions.

**Professor Nancy Klimas** (Miami, Florida) – reported on their genetic signature study. She pointed out that genetic studies are expensive, and large numbers of patients are needed – as many as 30,000 to be finding significant differences, therefore much funding is needed. She is part of a very large team. She outlined the symptoms of the illness.

Studies are being undertaken to determine diagnosis, genetic risk, explanation of the illness and prediction of therapy. The gene study is unique and a huge challenge. Is there a genetic signature which determines why one person recovers and another remains ill?
Students are using social media to recruit participants, who are asked to donate data rather than dollars. Development of a registry can be done on line, finding out history, illness progression etc. Many answers may be found.

Basic single nucleotide polymorphism (SNP) methods can be used. A SNP is a single mutation in a gene – we have thousands of these (maybe 10 million), which make us the individuals we are. The approach using genetic data and symptom questionnaires could be used to look at potential treatments, diagnostic tests etc. Targeted treatments could be developed and tailored.

The main barrier is money. Brainstorming is a very useful approach, with aggressive partnerships and more student power. Developments over 18 months are already in progress. The smallest number of participants to discover one abnormal SNP association is about 800. She said we need the “help of the world” and this project needs to “go viral”.

**Dr Jakob Theorell** (Karolinska Institutet, Sweden) works focussing on the understanding of the mechanisms of disease in patients suffering from chronic immunodeficiency syndromes. As an example of his work he initially discussed a rare potentially fatal disease in babies - Familial hemophagocytic lymphohistiocytosis (FHL), a *disorder* in which the immune system produces too many activated T cells.

He has been studying NK cells and cytotoxic T-cells in ME/CFS. SNPs keep us in balance. Cytotoxic lymphocytes, part of our immune memory, have been found in other studies to be dysfunctional in ME/CFS. Effector cells attach to target cells. Assays using whole blood lymphocytes can be used to detect the impairments. Variables could select patients from controls. Cytotoxic lymphocyte counts can be done as well as looking at cytotoxic proteins. In ME/CFS, NK cell “killing” is reported as reduced.

His study was on 48 patients from 2 cohorts and matched controls. Consistent differences were not found between patients and controls in cytotoxic lymphocyte numbers, cytotoxic granule content, activation status, exocytotic capacity, target cell killing, cytokine production or reprogrammed NK cell expansions. He concluded therefore that NK function could not be used as a biomarker for ME/CFS. Adrenaline may be important and there may be down-regulation of adrenaline receptors, responsible for lymphocyte defects.

**Professor Jo Cambridge/Fane Mensah** (University College Hospital, London) – works in the area of B-cell depletion treatment (Rituximab) in rheumatoid arthritis. Rituximab only works in sero-positive patients, not sero-negative. After treatment there is a delayed return of B cells – memory cells having been left behind, leading to gradual repopulation of the B cells. The number of B cells returning is not related to relapse. Rituximab works if auto-immunity is present. It stops new B cells differentiating to plasma cells. It also stops the interaction of B cells with T cells. Relapse occurs when B cells start to mature. An aberrant immune response is occurring. There are 2 types of patients: responders and non-responders.

Cell differences include: memory-1 marginal zone B cells associated with IgM, CD24 which has a role in B cell maturation. CD21 which decreases over time and correlates with disease duration. Marginal zone (MZ) B cells are a subset of peripheral B cells that with other cell types may be important in the induction of auto-immune disease.
MZ B cells were discussed in relation to the antibody response to Epstein Barr Virus (EBV).:

Phase 1 – IgM antibody recognizes carbohydrates, IgM paints the infected cell, then fixes c-
lysis. In Phase 2 the proper immune response kicks in with innate B cells. These do not make
many antibodies, are associated with auto-immunity and drive the auto-immune response.
In EBV the IgM is activated. In ME/CFS the IgG EBV antibody may be lower. Carbohydrate is
recognized and has effects. There is increased expression of CD24 on B cells. There is high
retention of CD24 on B cells, but this is age dependent and is lost with increased age. The
mitochondrial mass in B cells is lower in ME/CFS.

Their conclusions were that B cell subsets can be used to test metabolic changes. Antibodies
can be involved in ME/CFS, and is there perhaps a role of metabolic processing in ME/CFS?

Professor Simon Carding (Norwich, UK) presented his team of young researchers from the
University of East Anglia, who are researching the gut virome.

1. Fiona discussed the differences between the healthy and unhealthy gut. She described
   how a viral infection could cause inflammation and change in the microbiome. There
could then be bacterial leakage into the bloodstream with auto-immunity.
2. Ernie had looked at faecal samples for viral isolation and viral DNA extraction and
   sequencing. The viral inflammation could lead to leaky gut. He was looking to see if the
viruses isolated could influence and/or kill their bacterial hosts in the gut.
3. Fiona then had looked at sequencing the viruses and coding DNA, putting this on the
   computer leading to viral informatics. Viral genomes are not yet characterized, and are
   often very similar.
4. The next presentation looked at the differences in the microbiome in ME/CFS. There
   was reduced diversity in the gut. Gut leakiness may link with the immune system. IgM
antibody is secreted into the gut to cope with the bacteria. This may affect gut
permeability. It is possible to separate the IgA negative and IgA positive bacteria.
5. Catherine had looked at the bacteria in the gut in relation to auto-immunity.

The aim of all this work was to look at suppression of the immune response – possibly with
drugs, to look at bacterial therapy (possibly faecal transplants) and to do a Rituximab clinical
trial.

Associate Professor Mady Hornig (Columbia University, NY, USA) discussed gut
metabolome-immune disturbances in ME/CFS subsets. She firstly reviewed the metabolome
and immune disturbances. She discussed the influences of genetic factors, epigenetic
regulation and environmental exposures during pregnancy and later life. Infection and immune
factors have been shown to be relevant in some brain disorders. Normal microbiota modulate
brain development. There is often gastro-intestinal co-morbidity in brain conditions (e.g.
Irritable bowel syndrome in ME/CFS). In ME/CFS there is less diversity of the microbiota.
Toxins, bacteria and undigested foods can escape into the bloodstream.

There has been a staged strategy for pathogen discovery in immune-related brain disorders.
Many viruses and bacteria have been proposed as possibly associated with ME/CFS. Viruses
are likely to activate immune signaling in the CNS. She discussed profiles of immune markers, mechanisms of fever production and development of POTS. Viruses entering the brain can be associated with circulating cytokines crossing the blood-brain barrier (BBB) and with sympathetic NS activity.

Distinct plasma immune signatures in ME/CFS are present early on. IFNα changes with duration. Inter-cytokine networks also change with duration.

They had also looked at the cerebro-spinal fluid (CSF). There were reduced levels of a number of cytokines. There was a difference in regression model of association of cytokines.

Bacteria from the microbiome can cross the BBB to cause microglial effects. There may be an autoimmune basis.
The metabolome can affect such things as intestinal motility. These are very complex systems: e.g. Microbiota→ Metabolome→ Brain axis
There is a need to look at patients with and without IBS.

Professor Olav Mella (University of Bergen, Norway) – started by giving a review of their clinical studies focusing on the use of RituxME (rituximab) and CycloME (cyclophosphamide). Earlier studies indicated that B-lymphocyte depletion may result in symptom improvement in a subgroup of ME/CFS patients. A Phase 3 double-blind, placebo-controlled intervention study with rituximab is now underway and due to be unblinded in October 2017.

In the earlier rituximab trials, responses were transient and as B cells returned there was likelihood of relapse. Maintenance treatment therefore seems likely to be needed. Maintenance of the drug increased the response. The study of severe patients had to be stopped because of difficulties in getting patients to hospital. There was often a lag time before response. Auto-antibodies are likely to be involved. This all gave rationale for further studies. There is a need to look at dosage, resultant quality of life and overall improvement. This led to the Phase 3 study. Money was raised for a national RituxME study. 152 patients are enrolled. Treatment is not to be used outside clinical trials. There are occasional serious side effects.

The cyclophosphamide trial resulted from a positive response by 2 out of 3 breast cancer patients treated with the drug, who also had ME/CFS. The level of the dose is very different in non-cancer patients. This study will finish in July. So far there are some good responses. The drug induces an early menopause.

A new study has been started with CycloME with slightly less frequent injections. They also want to do metabolite analysis on the serum, and also look at the effects of patient serum on metabolites. They are finding that normal cells behave differently in ME/CFS serum, than in controls.

His conclusions were: ME/CFS is an immune system disease, with mitochondrial abnormalities and a lack of ATP. There are thus widespread symptoms from multiple systems, with
compensation mechanisms. When improving, all symptoms appear to improve simultaneously. Their future depends on the outcome of the rituximab study, and the pursuit of cyclophosphamide intervention.

Dr Ingrid Rekeland (Bergen, Norway) discussed more of the Norwegian work on behalf of Prof Øystein Fluge, who was recovering from injury. She discussed the likely obstruction of metabolic pathways in ME/CFS. She raised the questions as to whether this is an immunological variance of an auto-immune disease, and what are the biological effector systems. She cited the fact that B vitamins are coenzymes in the pyruvate dehydrogenase (PDH) complex, and this is closely related to the TCA cycle and electron transport train. The amino acid pattern suggested functional impairment of pyruvate dehydrogenase, supported by increased mRNA expression of the inhibitory PDH kinases.

Professor Warren Tate (University of Otago, New Zealand) started by explaining how he, as a biochemist had come to be involved in ME/CFS research. His 14 year old daughter had developed the illness after EBV. He graphically likened the research to the piecing together of a jigsaw puzzle. He is researching a small number of patients employing the technique of Precision Medicine (many tests on a small number of patients).

MicroRNAs control all our physiology, and their study reflects what is going on in the body. Data has been collected on the transcriptome and the proteome as well as plasma microRNAs and cytokines, with the aim of integrating the data to elucidate linkages between different classes of molecules, and to give insight into physiological changes. Functional connections were shown between 9 out of 10 upregulated genes when the transcriptome was examined. A number of biochemical pathways are modulated. There is phosphorylation of protein kinase R in a chronically activated immune system. The PKR ratio in lymphocytes is elevated in ME/CFS and this has promise for further research.

A small 10 patient study focusing on exercise intolerance and biochemical changes is also underway. Studies will be extended to include mitochondrial function and epigenetic changes in the DNA, particularly in relation to factors perpetuating the illness.

The idea was discussed of the potential value of studying one patient long-term with regular (say monthly) analyses of many biochemical and immune parameters. This would be particularly important to see what was occurring during relapses and remissions.

Professor Ron Davis (Stanford, California, USA) also has pioneered his ME/CFS research as a result of having a severely ill son. He says this is no doubt a molecular disease, and there have been many molecular breakthroughs. New technology is developing fast. The aims should be to look at the mechanism of the disease, a diagnostic tool and then treatment. A biomarker needs to be inexpensive. And there is opportunity to develop molecular therapies. There is always difficulty with funding.
He wants to develop new technologies which will reduce health costs. He encourages development of precision medicine approaches to understand and treat disease.

He showed a flow chart to enhance understanding of the way the underlying mechanisms link together:

```
Immune system ←← Infection, stressors, auto-immune trigger
↑       ↓       ↓
Genetics→→            ↓        ↓→→→→
↓           ↓
↓
Metabolism →→→Post-exertional malaise
           Neuromuscular symptoms
```

Genome sequencing can be done as it is less costly. His team is using a Big-Data approach: 20 severely ill patients, 10 controls and 8 families (including unaffected members who are ideal controls). The overall number of controls is reduced as each analysis for them costs as much as for the patients. A very long list of factors which are being measured was shown.

Various results and ongoing studies, innovations and potential studies were presented:

1. Cell free DNA quantification of 20 SIPs samples and 10 controls – 2 out of the very severe patients showed up very high levels.
2. Multiplex viral sequencing in clinical samples with analyses of viruses. No viruses were detected in most ME/CFS patients. Healthy controls had more viruses than the patients.
3. Search for new pathogens – This was complex analysis but no new pathogens were found. 2 TT viruses were found, but controls had more than the patients.
4. Mitochondrial DNA in the severely ill – the same as in healthy controls
5. Cytokine levels track with phenotype severity – results will be on the Open Medicine Foundation website.
6. Disrupted metabolomics – here there is great complexity. There are some deficits and some surplus. 193 metabolites were examined. This relates to the TCA cycle. There was not the same result for all patients. Results were different to those found by Naviaux.
7. Lactate, glucose, sodium and potassium can all be measured using a sweat band, but this is expensive and a small inexpensive chip has been designed by Ron Davis.
8. The power of induced pluripotent stem cells – can be produced from blood for an infinite supply of various cell types.
9. Can use CRISPR genome editing technology.
10. A diagnostic test is needed. A nano-needle biosensor can be used to detect cells and molecules via electric signals. Adding sodium chloride gives a clearer signal. But results do need to be tested against other diseases. A simple silicon chip may be developed and cheaper to use. Maybe only 1c – a circuit on a chip for cell sorting, but a software programme would be needed for interpretation.

12. Magnetic levitation device – separates cells and can potentially identify ME/CFS patients.

The important thing now is to share analyses with other researchers.

Finally he discussed the fact that patients may get benefit from side effects from drugs used in other illnesses. For example, Suramin, an old drug discovered in 1916, is used in Africa to treat sleeping sickness. It shuts down the serogenic receptor, and works by inhibiting the signaling function of adenosine triphosphate (ATP). It is being trialled for use in autism. It is also possible it may help in ME/CFS. One dose only, administered IV may be needed. But the drug is not now easily available.

The conference concluded with a question and answer session and comments from Dr Ian Gibson about how far and excitingly the research has advanced. Invest in ME Research were thanked for the enormous amount of effort put in to organizing this event.

I must thank both Invest in ME Research and ANZMES for their support in helping me to attend this conference.

Rosamund Vallings MNZM, MBBS
Auckland, NZ